Investors should monitor upcoming Phase 2a 8-week follow-up data in Q2 2026 and the start of the Phase 3 FOS trial. The Tenacia deal de-risks the China development path and provides non-dilutive capital. The extended cash runway reduces near-term financing risk, supporting continued pipeline advancement.
Price Chart
Executive Summary
Rapport Therapeutics reported its 2025 financial results alongside significant clinical and strategic progress, highlighted by robust Phase 2a data for RAP-219 in focal onset seizures, an accelerated Phase 3 initiation timeline, expansion into primary generalized tonic-clonic seizures, and a $328M strategic collaboration with Tenacia Biotechnology for Greater China. Despite a wider net loss, the company ended 2025 with $490.5M in cash, extending its runway into mid-2029.
Key Financial Metrics
Key Facts
- RAP-219 Phase 2a trial in focal onset seizures showed 77.8% median reduction in seizure frequency (p=0.01), 72% of patients achieved ≥50% reduction, and 24% achieved seizure freedom.
- Phase 3 trial in focal onset seizures now expected to start in Q2 2026 (accelerated from Q3 2026).
- New Phase 3 trial in primary generalized tonic-clonic seizures (PGTCS) planned for H1 2027.
- Strategic collaboration with Tenacia Biotechnology for Greater China: $20M upfront, up to $308M in milestones, and mid-single to mid-teens tiered royalties.
- Cash position of $490.5M at year-end funds operations into the second half of 2029.
- Net loss for full year 2025 was $111.5M vs. $78.3M in 2024, driven by increased R&D and G&A spending.
Financial Impact
Up to $328M in potential payments from Tenacia deal (including $20M upfront and $308M in milestones); $490.5M cash runway into 2029.
Risk Factors
- RAP-219 remains in clinical development; regulatory approval is not guaranteed.
- Increased net loss and cash burn could pressure valuation if milestones are delayed.
- Reliance on third parties for clinical development and manufacturing introduces execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252612 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers